M1328 HCPCS Level II code: Patients with a diagnosis of acute vitreous hemorrhage

M1328 is the HCPCS code for “Patients with a diagnosis of acute vitreous hemorrhage” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

M1328

Patients with a diagnosis of acute vitreous hemorrhage

Short description: Pts dx acute vitreous hem

HCPCS · United States

Medicare details

The indicators CMS publishes with M1328 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
Type of service
Medical care
BETOS category
Undefined codes
Added
Jan 1, 2024

Where M1328 sits

  1. 1M codesMedical services and quality measures
  2. 2Active code M1328Patients with a diagnosis of acute vitreous hemorrhage

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code M1328 mean?

M1328 is the HCPCS code for “Patients with a diagnosis of acute vitreous hemorrhage” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover M1328?

CMS lists M1328’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.

M1322Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop =<25 mm hg for injected eyeM1323Patients seen within 7 weeks following the date of injection and are screened for elevated intraocular pressure (iop) with tonometry with documented iop >25 mm hg and a plan of…M1324Patients who had an intravitreal or periocular corticosteroid injection (e.g., triamcinolone, preservative-free triamcinolone, dexamethasone, dexamethasone intravitreal implant…M1325Patients who were not seen for reasons documented by clinician for patient or medical reasons (e.g., inadequate time for follow-up, patients who received a prior intravitreal or…M1326Patients with a diagnosis of hypotonyM1327Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 8 weeksM1329Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 8 weeks after initial acute pvd encounterM1330Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up)M1331Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than 8 weeks from initial examM1332Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within 2 weeksM1333Acute vitreous hemorrhageM1334Patients with a post-operative encounter of the eye with the acute pvd within 2 weeks before the initial encounter or 2 weeks after initial acute pvd encounter